RandyW Posted April 29, 2009 Share Posted April 29, 2009 UPDATE 1-Zeltia says Irvalec efficient for lung cancer Mon Apr 27, 2009 5:15am EDT Email | Print | Share | Reprints | Single Page [-] Text [+] MORE NEWS Zeltia says Irvalec efficient for lung cancer Monday, 27 Apr 2009 04:30am EDT MARKET NEWS Stock index futures point to Wall Street rising Positive earnings drive stocks higher; yen dips Oil rises above $50, buoyed by equities, data More Business & Investing News... * Promising results on other drugs also presented * Shares up 4 percent (Adds details, share price) MADRID, April 27 (Reuters) - Spanish biotechnology firm Zeltia (ZEL.MC) said on Monday that preclinical trials for its Irvalec drug have shown efficiency in treating lung cancer. The results were presented at an American Association for Cancer Research (AACR) conference in Denver from April 18-22, where Zeltia said it also presented promising data on other drugs in its pipeline. By 0913 GMT, Zeltia's shares were up 4 percent at 3.70 euros, its session high, compared to a 2 percent decline on Spain's leading Ibex-35 index .IBEX. As part of 14 new studies on Zeltia's marine-derived antitumour compounds presented at the AACR conference, the company's star drug Yondelis showed it was active as an inhibitor for Ewing's Sarcoma, or pediatric tumours. Yondelis is already sold in most of Europe to treat soft tissue sarcoma and is awaiting approval for the treatment of ovarian cancer in Europe and in the United States with partner Johnson & Johnson (JNJ.N). (Reporting by Tracy Rucinski) © Thomson Reuters 2009 All rights reserved Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.